Brought to you by 
Progenics, Wyeth develop GI compound MNTX; ends
30 Nov 2009
Executive Summary
Progenics licensed Wyeth Pharmaceuticals exclusive worldwide development and commercialization rights to its methylnaltrexone (MNTX) to treat side effects induced by opioid pain treatments. The deal enables Wyeth to further expand its reach into the gastroenterology field.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Progenics, Wyeth develop GI compound MNTX; ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice